←
M PREMKUMAR849 posts
M PREMKUMAR avatar

M PREMKUMAR

@docMPK

Stranger in a Strange Land

◷ Joined May 2021▧ 142 Photos and videos
Dr Ashish Kumar avatar
⟳ M PREMKUMAR retweeted
Dr Ashish Kumar@DrAshish_Kumar·Aug 27

🧬 Our new paper in @JCEH_Hepatology is out! In 69 North Indian MASLD patients genotyped for 12 candidate SNPs, we found that APOC3 and PNPLA3 operate on distinct genetic axes: 🔸 APOC3 rs2854116 — enriched in MASLD vs Indian population (OR 1.93, P<0.001) but NO fibrosis association → susceptibility variant 🔹 PNPLA3 rs738409 — strongest fibrosis predictor (OR 2.89, P=0.006) → severity variant 🔥 Carriers of risk alleles at ALL 3 loci (APOC3+PNPLA3+SAMM50) had 90% fibrosis prevalence (OR 13.7, P=0.0001) Who gets the disease ≠ who gets worse. Ancestry-specific genetic data matter. #MASLD #LiverTwitter #Genetics #PNPLA3 #APOC3 #Hepatology #JCEH #IndianGenomics sciencedirect.com/science/ar…

Post attachment
M PREMKUMAR avatar
M PREMKUMAR@docMPK·Aug 16

Liver stiffness at SVR-48 (aHR 1.01, 95% CI: 1.001–1.030, P = 0.021) and ALBI score at SVR-12 (aHR 1.31, 95% CI: 1.1–1.4, P = 0.034) predicted de novo HCC. Recurrence rate ⬇️patientswith de novo HCC than in those with HCC at presemtation. 5year🇮🇳 cohort. @JCEH_Hepatology

Post attachmentPost attachmentPost attachment
M PREMKUMAR avatar
M PREMKUMAR@docMPK·Aug 16

HCC in GT 3 HCV 🇮🇳 kwnsfk27.r.eu-west-1.awstrac… De novo HCC post SVR-12 in HCV compensated cirrhosis. was in 128/3994 (3.2%), median follow-up of 4 years, an incidence of 985 per 100,000 person-years; 77.3% men, 71.6% genotype-3, BCLC stages were A (60.2%), B (28.9%), and C (10.9%).

Post attachmentPost attachment
Anand V Kulkarni avatar
⟳ M PREMKUMAR retweeted
Anand V Kulkarni@AnandVKulkarni2·Aug 13

Continuing our work on recomp- 1/3rd of AIH also can recomp. AIH-PBC -25% AIH-PSC none link.springer.com/article/10… @RoyAHep @karanbjmc93 @docMPK @BavenoCoop @ReibergerThomas @JimmyLaiCT @TerryYip12 #LiverX

🚨 Recompensation in decompensated AIH cirrhosis 🔹34% achieved Baveno VII recompensation 🔹 Transplant-free survival was 97% vs 63%* with vs without recompensation 🔹 20% re-decompensated Recompensation in AIH is real but dynamic. link.springer.com/article/10…

Akash Roy avatar
⟳ M PREMKUMAR retweeted
Akash Roy@RoyAHep·Aug 13

🚨 Recompensation in decompensated AIH cirrhosis 🔹34% achieved Baveno VII recompensation 🔹 Transplant-free survival was 97% vs 63%* with vs without recompensation 🔹 20% re-decompensated Recompensation in AIH is real but dynamic. link.springer.com/article/10…

M PREMKUMAR avatar
M PREMKUMAR@docMPK·Aug 7

Recompensation of decompensated cirrhosis in a spectrum of metabolic dysfunction-related steatotic liver disease, with PEth-corroborated alcohol abstinence and modification of cardiometabolic risk factors. Hepatology. 2026 Jul 17. PMID: 42467948.

Post attachment
Akash Roy avatar
⟳ M PREMKUMAR retweeted
Akash Roy@RoyAHep·Apr 19

🇮🇳 Real-world data from >1000 patients with MASLD/MetALD MRI-PDFF phenotyping + 🧲 MRE anchor 🔍 Key takeaways: ✔️ Similar CMRF & AF burden ✔️ FIB-4 & NFS perform well ❌ APRI underperforms 💡 Simple NITs even for MetALD @AnandVKulkarni2 @DrMaheshgoenka link.springer.com/article/10…

Dr Ashish Kumar avatar
⟳ M PREMKUMAR retweeted
Dr Ashish Kumar@DrAshish_Kumar·Mar 27

#Fibrosis prevalence across clinical subgroups: Highest: CAD (33%), eGFR <60 (33%), Obesity (32%), Dyslipidaemia (30%) Even without obesity: 19% Dashed line = overall prevalence (26%). No difference by sex or hypothyroidism. Fibrosis is widespread across ALL subgroups.

Post attachment
Nikita Sharma avatar
⟳ M PREMKUMAR retweeted
Nikita Sharma@sharmanik·Mar 24

*New Issue Alert* The special IJG Women and Gastroenterology March-April issue (Volume 45, Issue 2) is online. Please have a look: link.springer.com/journal/12… @IJG_Journal @docMPK @drvishal82 @drsridhars @DrAnuraagJ @giri_gutnliver @UshaPGIMER